Royalty PharmaFRA:RPD +3.65%68 Buyback Yield % is 2.22 as of Jul. 03, 2026, which is 13% below its 10-year median of 2.55. GuruFocus rates FRA:RPD with a GF Score™ of 68/100 and a GF Value™ of €32.39 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 744 Biotechnology companies, Royalty Pharma ranks better than 97.04% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Royalty Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RPD vs ROIV, MRNA, BNTX: Buyback Yield % Comparison
For the Biotechnology subindustry, Royalty Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (FRA:RPD) has a Buyback Yield % of 2.22 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Royalty Pharma and its competitors. This is 13% below median its historical median of 2.55. According to the industry distribution chart, Royalty Pharma ranks #22 out of 744 companies in the Biotechnology industry, placing it in the top 3%.
Is Royalty Pharma's Buyback Yield % too high?
Royalty Pharma's current Buyback Yield % of 2.22 is 13% below median its 10-year median of 2.55. Based on the distribution chart, Royalty Pharma ranks #22 out of 744 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Royalty Pharma has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Buyback Yield % compare to ROIV and MRNA?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #22 out of 744 companies for Buyback Yield %. This places Royalty Pharma in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Buyback Yield % is 2.22, which is 13% below median its own 10-year median of 2.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.39, compared to a current price of €49.47 — trading 52.7% above its estimated fair value. The current Buyback Yield % is 2.22, which is 13% below median its 10-year median of 2.55. Royalty Pharma's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Buyback Yield % is 2.22 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (FRA:RPD) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of €49.47 is trading 52.7% above its estimated GF Value™ of €32.39.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for FRA:RPD:
Buyback Yield %: 2.22 (13% below median its 10-year median of 2.55)
GF Value™: €32.39 vs. price of €49.47 (52.7% above fair value)
No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
68GF Score
Get the complete analysis for FRA:RPD
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RPD has been successfully added to your 
